Amarin Corporation plc (AMRN:NASDAQ) closed at $11.51 on October 21, 2026, up 0.26% on the day. The stock trades 44.9% below its 52-week high of $20.90 and 2.3% above its 52-week low of $11.25. Over the past year, it lost 41.3%. Amarin Corporation plc is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 21, 2025, AMRN closed higher on 117 days (46%). Its best day was January 8, 2026 (+16.89%) and its worst was October 29, 2025 (-11.25%). The stock moved 10% or more in a single session 2 times.
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.
Find more stocks like AMRN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.